Background
Researchers have indicated that they want access to novel target antibodies quickly to aid in their research. IMGENEX is pleased to be able to offer researchers access to cutting-edge products that are still in the process of characterization/validation. IMGENEX’s ‘IMX’ antibody line is shown by ELISA to bind to the peptide used as immunogen. Investigators should empirically determine the suitability of the antibody, including optimal dilutions, for other applications of interest.
 |
We cannot guarantee that the yet-to-be-fully validated antibody will work in any application other than in an ELISA against the peptide used as immunogen and therefore cannot offer a refund if the antibody does not work in your application. |
|
The antibody is offered at a lower price compared to a more highly validated antibody. |
|
We are not able to provide the immunogen for the antibodies, but do provide the amino acid sequence. |
These antibodies are not fully validated and we appreciate your feedback. Customer feedback is used to help generate testing methodologies which can lead to further product validation or withdrawal.
Principal Names: ACVRL1; HHT; ALK1; HHT2; ORW2; SKR3; ALK-1; ACVRLK1; activin A receptor type II-like 1; Activin A receptor, type II-like kinase 1. Official Symbol: ACVRL1. GenBank Accession Number(s): NP_000011. GeneID: 94 (human). Gene Ontology Terms: transmembrane receptor protein serine/threonine kinase; TGFbeta receptor signaling pathway; circulation; integral to plasma membrane. Important Comments: Note must not to be confused with the similarly named ALK (anaplastic lymphoma kinase). |
Reference
1. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous ME, Marchuk DA.
Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2.
Nat Genet. 1996 Jun;13(2):189-95.
PMID: 8640225
|
